Cyclana Bio raises £5 million to advance novel endometriosis therapies

UK start-up Cyclana Bio has secured £5 million ($6.1 million) in pre-seed funding to advance its platform targeting women’s health through tissue-level therapeutics, starting with endometriosis. The round was co-led by NfX and Eka VC, with participation from Cocoa VC, Wilbe, and several angel investors.

Based in Cambridge, the company is developing functional disease models that replicate the biology of endometriosis more accurately than current methods. Cyclana Bio’s technology integrates tissue samples with AI-driven data analysis to uncover new therapeutic targets and improve drug discovery outcomes. The platform builds on the firm’s research into the extracellular matrix (ECM), which it says plays a key role in driving inflammation and tissue dysfunction in the condition.

Endometriosis is a chronic and often debilitating inflammatory disease affecting about one in ten women of reproductive age, or roughly 190 million globally. Current treatments largely target hormone regulation or intracellular pathways, with limited long-term benefit. Cyclana Bio’s focus on ECM dysregulation aims to address this gap by exploring how tissue-level mechanisms shape disease progression.